尤瑞克林治疗急性脑梗死的临床观察

Case-control study of therapeutic effect of urinary kallidinogenase for acute cerebral infarction

目的观察尤瑞克林治疗急性脑梗死的疗效。方法将91例急性脑梗死患者随机分为治疗组和对照组,两组基础用药均为血栓通注射液500mg1/日+阿司匹林0.1g1/晚。其中治疗组46例,除基础用药外,另用尤瑞克林0.15PNAU加生理盐水250ml静滴1次/日;对照组45例仅用基础用药。使用美国国立卫生研究所脑卒中评分(NIHSS)和残疾指数(mRS Index)评价神经功能恢复情况。结果(1)治疗14天后,尤瑞克林治疗组的NIHSS评分、mRS评分较对照组有明显改善(P<0.05);治疗组有效率高于对照组(86.96%vs75.56%),差异有统计学意义(P<0.05)。(2)两组均未发生明显不良反应。结论尤瑞克林治疗急性脑梗死安全有效。

Objective To evaluate the efficacy of human urinary kallidinogenase in treating patients with acute cerebral infarction. Methods Ninety-one patients with acute cerebral infarction were randomly divided into two groups in this study; the treatment group were given urinary kallidinogenase ,Xueshuantong injection and aspirin; and the control group were treated by Xueshaangtong injection and aspirin. The National Instiutes of Health Stroke Scale （NIHSS） ,mRS Index and therapeutic outcomes in the two groups were addessed before treatment and 14 days after initiating treatment. Results （ 1 ） The NIHSS and mRS in the two groups were inproved after treatment , but those in the treatment group was incereased more dramatically, showing significant difference form those in control groups（ P 〈 0.05 ）. Curative effect of treatment group was better than that of control group（ P 〈 0.05 ）, the difference being significant. （ 2 ） No drug adverse reaction were found in two groups. Conclusion Urinary kallidinogenase is ef- ficatious for acute cerebral infarction in improving the neurological deficits ,which is safe in clinical use.